Skip to Content

Enzepi

Active Substance: pancreas powder
Common Name: pancreas powder
ATC Code: A09AA02
Marketing Authorisation Holder: Allergan Pharmaceuticals International Ltd
Active Substance: pancreas powder
Status: Withdrawn
Authorisation Date: 2016-06-29
Therapeutic Area: Exocrine Pancreatic Insufficiency
Pharmacotherapeutic Group: Digestives, incl. enzymes

Therapeutic Indication

Pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).
Enzepi is indicated in infants, children, adolescents and adults.

The marketing authorisation for Enzepi has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide